Prognostic role of C-reactive protein in hepatocellular carcinoma: A systematic review and meta-analysis

International Journal of Medical Sciences

Volumn 10, Issue 6, 2013, Pages 653-664

  Zheng, Zhiyun ^a   Zhou, Lin ^a   Gao, Sheng ^a   Yang, Zhe ^a   Yao, Jia ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

C reactive protein; Hepatocellular carcinoma; Prognosis; Survival

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SENSITIVITY ANALYSIS; TUMOR VOLUME;

C-REACTIVE PROTEIN; HEPATOCELLULAR CARCINOMA; PROGNOSIS; SURVIVAL.;

C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PUBMED;

EID: 84875881139     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6050     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013; 63:11-30.
3. Tillett WS, Francis Jr T. Serological reactions in pneumonia with a non-protein fraction of pneumococcus. J Exp Med.1930;52:561-571.
4. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C reactive protein formation. J Exp Med.1966; 123: 365-378.
5. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 2009; 48: 111-136.
6. C.A. Janeway Jr., R. Medzhitov, Innate immune recognition, Annu. Rev. Immunol. 2002;20:197-216.
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340: 448-454.
8. Erlinger T, Platz E, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. J Am Med Assoc. 2004; 291: 585-590.
9. Nozoe T, Matsumata T, Kitamura M, et al. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg.1998; 176: 335-338.
10. Wang CY, Hsieh MJ, Chiu YC, et al. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol. 2009; 92: 255-270.
11. Pine JK, Fusai KG, Young R, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2009; 35: 605-610.
12. Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007; 110: 1241-1247.
13. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008; 14: 710-4.
14. Herishanu Y, Perry C, Braunstein R, et al. Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lym-phoma. Eur J Haematol. 2007; 79: 150-154.
15. Zahlten-Hinguranage A, Goldschmidt H, Cremer FW, et al. Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br J Cancer. 2006; 95: 782-787.
16. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 1994; 69: 911-913.
17. Wells GA, Brodsky L, O'Connell D, et al. An Evaluation of the Newcastle Ottawa Scale: An Assessment Tool for Evaluating the Quality of Non-Randomized Studies. XI International Cochrane Colloquium Book of Abstracts.2003; XI Cochrane Colloquium Vol.O-63:26.
18. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med.1998; 17: 2815-2834.
19. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
20. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.
21. Ishizuka M, Kubota K, Kita J, et al. Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. J Surg Oncol. 2011;103:801-806.
22. Imai N, Kinoshita A, Onoda H, et al. Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clin Transl Oncol. 2012; [Epub ahead of print].
23. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellu-lar carcinoma. Cancer. 2005;103:1856-1864.
24. Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27:1091-1097.
25. Chun JM, Kwon HJ, Sohn J, et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol. 2011;103:148-151.
26. Bertuzzo VR, Cescon M, Ravaioli M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation. 2011;91:1279-1285.
27. Ishizuka M, Kubota K, Kita J, et al. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg. 2012;203:101-106.
28. Kohles N, Nagel D, Jüngst D, et al. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33-40.
29. Jang JW, Oh BS, Kwon JH, et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60:686-693.
30. An HJ, Jang JW, Bae SH, et al. Serum C-reactive protein is a useful bi-omarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2012;18:1406-1414.
31. Sieghart W, Pinter M, Hucke F, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology. 2012;[Epub ahead of print].
32. Kinoshita A, Onoda H, Takano K, et al. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol. 2012;29:2800-2808.
33. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62:394-399.
34. Gluer AM, Cocco N, Laurence JM, et al. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB(Oxford). 2012;14:285-290.
35. Lim KC, Chow PK, Allen JC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108-113.
36. Zheng SS, Xu X, Wu J et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation.2008;85:1726-1732.
37. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197-208.
38. Maeda S, Hikiba Y, Sakamoto K, et al. Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology 2009;50:1851-1860.
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
40. Dufour JF. CRP, a prognostic marker in HCC. Hepatology. 2013; [Epub ahead of print].
41. Cervoni JP, Thévenot T, Weil D, et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol. 2012; 56: 1299-1304.